Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 113 | 33% |
| 2020 | 0 | 71 | 36% |
| 2021 | 0 | 91 | 39% |
| 2022 | 0 | 89 | 41% |
| 2023 | 0 | 87 | 43% |
| 2024 | 0 | 107 | 45% |
| 2025 forecast | – | 109 92–128 | 46% |
| 2026 forecast | – | 111 87–140 | 46% |
| 2027 forecast | – | 113 84–150 | 47% |
| 2028 forecast | – | 115 82–159 | 47% |
| 2029 forecast | – | 117 80–168 | 47% |
| 2030 forecast | – | 119 78–177 | 48% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2019, 100% hospital outpatient.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 3 | 512+0.8%/yr | +0.8%/yr | 0.3 | 0% | 600 in 2030+2.7%/yr |
| Massachusetts | 4 | 431−1.7%/yr | −1.7%/yr | 0.5 | 0% | 590 in 2030+5.3%/yr |
| Pennsylvania | 3 | 418+0.9%/yr | +0.9%/yr | 0.3 | 0% | 330 in 2030−3.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 124 | 7,0630%/yr | 0%/yr | 7.10.8× | 39% | 8,480 in 2030+3.1%/yr |
| Tumor & fibroid embolization | 4 | 287+0.9%/yr | +0.9%/yr | 0.30.4× | 22% | 820 in 2030+19%/yr |
Tumor ablation in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Exact Sciences leads with 52% of company spending on these surgeons in 2025, −4 pts on 2024.
In 2025, 18 companies reported engagement with New Jersey’s surgeons worth $472K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.